SCHEMBL23693716

SCHEMBL23693716

CCNS(=O)(=O)Nc1nccc(Cc2cc(C(N)=O)c(Nc3ccc(C)cc3F)cc2F)c1F

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAP2K1 Q02750 12/20 0.41
▸ MAP2K2 P36507 9/20 0.41
▸ CSF1R P07333 1/20 0.37
▸ HDAC3 O15379 1/20 0.34
▸ HDAC1 Q13547 1/20 0.34
▸ HDAC6 Q9UBN7 1/20 0.34
▸ KCNH2 Q12809 2/20 0.34
▸ SCN5A Q14524 1/20 0.34
▸ JAK2 O60674 1/20 0.33
▸ JAK1 P23458 1/20 0.33
▸ TYK2 P29597 1/20 0.33
▸ MAPT P10636 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ MAP2K4 P45985 1/20 0.32
▸ RAF1 P04049 2/20 0.32
▸ BRAF P15056 2/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ MAP2K5 Q13163 1/20 0.32
▸ DHODH Q02127 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24849393 0.92 MAP2K1 (0.43) MAP2K1MAP2K2CSF1RHDAC3HDAC1
SCHEMBL23693712 0.91 MAP2K1 (0.45) MAP2K1MAP2K2
SCHEMBL30459892 0.91 MAP2K1 (0.45) MAP2K1MAP2K2
SCHEMBL24849658 0.90 MAP2K1 (0.39) MAP2K1MAP2K2CSF1RHDAC3HDAC1
SCHEMBL24849354 0.89 CSF1R (0.40) MAP2K1MAP2K2CSF1RHDAC3HDAC1
SCHEMBL24849642 0.88 MAP2K1 (0.40) MAP2K1MAP2K2CSF1RHDAC3HDAC1
SCHEMBL24849668 0.86 MAP2K1 (0.40) MAP2K1MAP2K2CSF1RHDAC3HDAC1
SCHEMBL25720540 0.84 MAP2K2 (0.42) MAP2K1MAP2K2CSF1RHDAC3HDAC1
SCHEMBL25720524 0.84 MAP2K2 (0.45) MAP2K1MAP2K2CSF1RHDAC3HDAC1
SCHEMBL23693713 0.83 MAP2K1 (0.45) MAP2K1MAP2K2BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230270730-A1 COMPOSITION CONTAINING ARYLAMIDE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-08-31 — — US disclosed
US-20230002333-A1 ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-01-05 — — US disclosed
WO-2021149776-A1 ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY 中外製薬株式会社 2021-07-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230270730-A1 COMPOSITION CONTAINING ARYLAMIDE DERIVATIVE BRAF, NRAS, KRAS MAP2K1 17/4885MAP2K2 11/4885CSF1R 1365/4885
US-20230002333-A1 ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY BRAF, NRAS, KRAS MAP2K1 162/4885MAP2K2 132/4885CSF1R 1142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback